Basiliximab
💊 Brand Formulations & Prices
1 brands sorted by unit price
📖 Official Clinical Monograph
DGDA Approved Prescribing GuidelinesSimulect is an immunosuppressant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with other agents. It has been reported that some cases of lichen planus have been successfully treated with Simulect as an alternative therapy to ciclosporin. No short-term side effects have been reported.
Known hypersensitivity to basiliximab or any component of the formulation
Serious side effect such as:
Pain or burning when you urinate
Easy bruising or bleeding, unusual weakness
Tremors, shaking
Fever, chills, body aches, flu symptoms, vomiting, diarrhea
Trouble breathing
Pale skin, feeling light-headed or short of breath, rapid heart rate, trouble
Re-exposure to a subsequent course of therapy in patient who has previously received Simulect. Children, Pregnancy and lactation.
Basiliximab functions as an IL-2 receptor antagonist by binding with high affinity to the alpha chain of the high affinity IL-2 receptor complex and inhibiting IL-2 binding. Basiliximab is specifically targeted against IL-2Rα, which is selectively expressed on the surface of activated T-lymphocytes. This specific high affinity binding of Basiliximab to IL-2Rα competitively inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection. While in the circulation, Simulect (basiliximab) impairs the response of the immune system to antigenic challenges. Whether the ability to respond to repeated or ongoing challenges with those antigens returns to normal after Simulect is cleared is unknown